Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 04/28 09:59:59 pm
8.45 USD   -0.59%
04/26 IMMUNOGEN : Appoints Mark J. Enyedy as President and Chief Executive..
04/18 IMMUNOGEN : Announces Initiation of Clinical Testing of First-in-Cla..
04/11 IMMUNOGEN : Announces Conference Call to Discuss its Third Quarter F..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,577,065,386,5
Operating income (EBITDA)-68,4-66,9-54,4-96,1-102-103
Operating profit (EBIT)-73,0-71,5-59,9-102-125-93,8
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-124-152-143
P/E ratio-19,1-14,3-20,3-5,98-5,23-5,77
EPS ( $ )-0,87-0,83-0,71-1,42-1,62-1,47
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.388.58.58.5
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt---10,188,5168
Finance195142278---
Operating income (EBITDA)-68,4-66,9-54,4-96,1-102-103
Leverage
(Debt/EBITDA)
----0,10x-0,86x-1,63x
Capital Expenditure3,778,187,4315,216,617,5
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,71 $-1,59 $-2,43 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,27 $--
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 740 M$ -
Entreprise Value (EV) 750 M$ 829 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 9,61x 11,3x
EV / Revenue 9,74x 12,7x
EV / EBITDA -7,81x -8,09x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -12,0x -5,35x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -133% -191%
operating Leverage (Delta EBIT / Delta Sales) -7,11x -1,44x
Net Margin (Net Profit / Revenue) -161% -233%
ROA (Net Profit / Asset) -45,9% -
ROE (Net Profit / Equities) 2 183% -
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   19,8% 25,5%
Cash Flow / Sales -144% -
Capital Intensity (Assets / Sales) 3,52x -
Financial Leverage (Net Debt / EBITDA) -0,10x -0,86x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend